Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Neuroscience Reaches A New Inflection Point, Big Biotechs Say

Executive Summary

Celgene and Biogen are investing in the challenging therapeutic area, fueled by advances in science, growing understanding of the role inflammation may play in neurodegenerative diseases and improved tools for measuring efficacy.

Advertisement

Related Content

Biogen's Neuroscience Strategy Includes De-Risking The Pipeline
Celgene's Positive Ozanimod Data Puts Focus On MS Commercialization
Biogen Builds Out Neuroscience Niche With Ischemic Stroke Drug
Biogen Builds In Neurodegenerative Disease With Anti-Tau Deal
Safety Is Key As Celgene's Ozanimod Succeeds In First Pivotal MS Test
Billions On The Line With Celgene’s Partnered Pipeline
Biogen/Ionis’s Spinraza Approved; Second Antisense Drug For Neurodegeneration In 2016
Biogen CEO Pick Vounatsos Suggests A Return To Commercial Focus
ECTRIMS 2016: Biogen Makes Headway in MS Remyelination Studies
Celgene Sets Sights On Becoming Inflammation and Immunology Power Player

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC098097

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel